On the public citation graph
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
Inferred edges come from two machine sources: sweeps of open repository
metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is
labelled with the one it came from. Neither is a complete citation index — absence here is not
evidence of absence.
1 of the 45 references listed on this page is in the Retraction Watch database as retracted (export 2026-11-18): 10.1210/jc.2014-2739 (notice 2015-05-01).
Dataset join, best-effort; this page does not check the publisher record.
Retraction Watch data via Crossref Labs, used with credit; OpenCitations Index (CC0) and Meta (CC BY 4.0);
dataset doi:10.7910/DVN/WT8VOA (CC BY 4.0).
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated
CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/hep.26156openalex-snapshotAssociation between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States
inferredcites →https://doi.org/10.1002/hep.27981openalex-snapshotPresence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study
inferredcites →https://doi.org/10.1002/hep.29367openalex-snapshotThe diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
inferredcites →https://doi.org/10.1002/hep.29724openalex-snapshotCurrent and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
inferredcites →https://doi.org/10.1002/hep.30842openalex-snapshotNoninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials
inferredcites →https://doi.org/10.1002/oby.23263openalex-snapshotType 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1055/s-0034-1371083openalex-snapshotHepatic Pathology among Patients without Known Liver Disease Undergoing Bariatric Surgery: Observations and a Perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) Study
inferredcites →https://doi.org/10.1097/mcg.0000000000001339openalex-snapshotAccuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1111/apt.13012openalex-snapshotFatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey
inferredcites →https://doi.org/10.1111/dom.12973openalex-snapshotNon‐alcoholic fatty liver disease ( NAFLD ) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes
inferredcites →https://doi.org/10.1111/jgh.14577openalex-snapshotScreening for non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography
inferredcites →https://doi.org/10.1111/liv.12840openalex-snapshotClinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients
inferredcites →https://doi.org/10.1111/liv.14669openalex-snapshotPrognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review
inferredcites →https://doi.org/10.1136/gutjnl-2015-309265openalex-snapshotScreening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study
inferredcites →https://doi.org/10.1136/gutjnl-2020-320622openalex-snapshotNAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
inferredcites →https://doi.org/10.1210/jc.2014-2739openalex-snapshotWITHDRAWN: High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels (article published in final form as 10.1210/jc.2015-1966)
inferredcites →https://doi.org/10.1210/jc.2015-1966openalex-snapshotHigh Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
inferredcites →https://doi.org/10.2337/dc11-1849openalex-snapshotPrevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
inferredcites →https://doi.org/10.2337/dc19-1071openalex-snapshotPerformance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc19-1113openalex-snapshotEconomic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
inferredcites →https://doi.org/10.2337/dc20-1778openalex-snapshotHigh Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc20-1997openalex-snapshotAdvanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
inferredcites →https://doi.org/10.2337/dc21-s004openalex-snapshot4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2021
inferredcites →https://doi.org/10.3390/jcm10091877openalex-snapshotPerformance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4840179openalex-extractedThe Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
inferred← citeshttps://doi.org/10.2139/ssrn.4893547openalex-extractedPrevalence and Risk Factors Associated with Hepatitis C Virus Infection in Patients with Type 2-Diabetes Mellitus; Case Control Study in Lahore, Pakistan
inferred← citeshttps://doi.org/10.1002/oby.23960openalex-snapshotNoninvasive tests to identify liver fibrosis in metabolic dysfunction‐associated steatotic liver disease are affected by race
inferred← citeshttps://doi.org/10.1002/oby.24130openalex-snapshotObesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen
inferred← citeshttps://doi.org/10.1002/oby.70277openalex-snapshotMajor Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/s11892-024-01558-yopenalex-snapshotNAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
inferred← citeshttps://doi.org/10.1016/j.aohep.2022.100762openalex-snapshotType 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis
inferred← citeshttps://doi.org/10.1016/j.aohep.2023.101177openalex-snapshotNon-linear associations of circulating total bilirubin concentration with the risk of nonalcoholic fatty liver disease and all-cause mortality
inferred← citeshttps://doi.org/10.1016/j.cgh.2024.01.032openalex-snapshotThe Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.dld.2025.05.023openalex-snapshotMultiparametric magnetic resonance imaging may improve detection of patients with at-risk MASH: Real world experience in hepatology clinics
inferred← citeshttps://doi.org/10.1016/j.dsx.2025.103209openalex-snapshotConsensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.ecoenv.2022.114361openalex-snapshotIntegration of metabolomics and proteomics reveals the underlying hepatotoxic mechanism of perfluorooctane sulfonate (PFOS) and 6:2 chlorinated polyfluoroalkyl ether sulfonic acid (6:2 Cl-PFESA) in primary human hepatocytes
inferred← citeshttps://doi.org/10.1016/j.endmts.2025.100218openalex-snapshotEffects of a novel weight-loss combination product containing orlistat and resveratrol on obesity: A multicenter randomized controlled study (EC-FIT)
inferred← citeshttps://doi.org/10.1016/j.eprac.2022.03.010openalex-snapshotAmerican Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
inferred← citeshttps://doi.org/10.1016/j.jep.2022.115268openalex-snapshotIntegrating metabolomics and network pharmacology to reveal the mechanisms of Delphinium brunonianum extract against nonalcoholic steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.metabol.2023.155642openalex-snapshotNonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States
inferred← citeshttps://doi.org/10.1016/j.tox.2024.153929openalex-snapshotEvaluating combined effects of chronic, low-dose exposures of cadmium (CLEC) and hyperglycemia on insulin signaling dysfunction in a hepatocellular model
inferred← citeshttps://doi.org/10.1093/ajhp/zxaf251openalex-snapshotPharmacist-led screening for advanced fibrosis using the FIB-4 index in patients 65 years or older with a clinical suspicion for MASLD at a family medicine clinic
inferred← citeshttps://doi.org/10.1093/fampra/cmag008openalex-snapshotCan the Finnish Diabetes Risk Score (FINDRISC) be used to predict liver fibrosis risk instead of the fibrosis-4 index (FIB-4)?
inferred← citeshttps://doi.org/10.1093/ofid/ofaf369openalex-snapshotPrevalence and Risk Factors of Liver Fibrosis Among People With HIV and Metabolic Dysfunction–Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1097/meg.0000000000002767openalex-snapshotMetabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease
inferred← citeshttps://doi.org/10.1111/dom.15153openalex-snapshotLiver fibrosis markers and all cause mortality in people with type 2 diabetes: A population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) Study)
inferred← citeshttps://doi.org/10.1111/dom.15524openalex-snapshotThe role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis
inferred← citeshttps://doi.org/10.1111/hepr.70089openalex-snapshotMetabolic Effect on Serum Mac‐2 Binding Protein Glycan Isomer Level and Its Normal Range in the Health Checkup Examinee
inferred← citeshttps://doi.org/10.1111/liv.15864openalex-snapshotLinks between gut microbiome, metabolome, clinical variables and non‐alcoholic fatty liver disease severity in bariatric patients
inferred← citeshttps://doi.org/10.1136/bmjgast-2024-001466openalex-snapshotForns index and fatty liver index, but not FIB-4, are associated with indices of glycaemia, pre-diabetes and type 2 diabetes: analysis of The Maastricht Study
inferred← citeshttps://doi.org/10.1136/bmjsem-2023-001878openalex-snapshotEffect of low-volume exercise on hepatic steatosis in adults with obesity plus normal glucose, prediabetes or type 2 diabetes: a randomised controlled trial
inferred← citeshttps://doi.org/10.1155/jdr/3955893openalex-snapshotNetwork Pharmacology and Serum Nontargeted Metabolomics Reveal the Protective Effects of Propionate Against Liver Damage Induced by a High‐Fat and AGE‐Rich Diet in Diabetic Mice
inferred← citeshttps://doi.org/10.1186/s12876-022-02550-0openalex-snapshotAssociation between hepatic steatosis and fibrosis with measures of insulin sensitivity in patients with severe obesity and type 2 diabetes - a cross-sectional study
inferred← citeshttps://doi.org/10.1186/s12889-024-19536-0openalex-snapshotSmoking, all-cause, and cause-specific mortality in individuals with diabetes in Mexico: an analysis of the Mexico city prospective study
inferred← citeshttps://doi.org/10.1186/s12933-022-01691-6openalex-snapshotThe association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study
inferred← citeshttps://doi.org/10.17925/ee.2025.21.1.4openalex-snapshotThe Use of Non-invasive Biomarkers to Screen for Advanced Fibrosis Associated with Metabolic Dysfunction-associated Steatotic Liver Disease in People with Type 2 Diabetes: A Narrative Review
inferred← citeshttps://doi.org/10.18203/2320-6012.ijrms20240665openalex-snapshotComparison of non-invasive scores predictive of development of metabolic dysfunction associated liver disease in patients of type 2 diabetes mellitus and evaluation of additive effect of smoking in these patients
inferred← citeshttps://doi.org/10.18553/jmcp.2026.32.10.1289openalex-snapshotEmbedding metabolic dysfunction–associated steatotic liver disease fibrosis risk stratification within pharmacist-integrated diabetes comanagement in primary care
inferred← citeshttps://doi.org/10.2147/dmso.s375300openalex-snapshotA Cross-Sectional Study of the Correlation Between the Atherogenic Index of Plasma and Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes
inferred← citeshttps://doi.org/10.2196/36997openalex-snapshotNoninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores
inferred← citeshttps://doi.org/10.2337/dc23-s004openalex-snapshot4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
inferred← citeshttps://doi.org/10.2337/dc24-s004openalex-snapshot4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024
inferred← citeshttps://doi.org/10.2337/dc25-s004openalex-snapshot4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025
inferred← citeshttps://doi.org/10.2337/dc26-s004openalex-snapshot4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026
inferred← citeshttps://doi.org/10.2337/dci24-0094openalex-snapshotMetabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
inferred← citeshttps://doi.org/10.2337/dsi23-0013openalex-snapshotRole of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
inferred← citeshttps://doi.org/10.2337/dsi23-0014openalex-snapshotMaking Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know
inferred← citeshttps://doi.org/10.2478/orvtudert-2024-0011openalex-snapshotAssessment of laboratory parameters in overweight/obese patients with type 2 diabetes mellitus and their relationship with cardiovascular risk factors
inferred← citeshttps://doi.org/10.3389/fendo.2026.1881759openalex-snapshotAssociation of the fibrosis-4 index with prevalent diabetes among adults: a cross-sectional analysis of NHANES 2003–2018 and a Chinese hospital-based health examination population
inferred← citeshttps://doi.org/10.3389/fnut.2023.1276940openalex-snapshotDietary and lifestyle oxidative balance scores are independently and jointly associated with nonalcoholic fatty liver disease: a 20 years nationally representative cross-sectional study
inferred← citeshttps://doi.org/10.3389/ijph.2023.1605031openalex-snapshotAssociation Between Physical Activity and Prevalence/Mortality of Non-Alcoholic Fatty Liver Disease in Different Socioeconomic Settings
inferred← citeshttps://doi.org/10.3390/diagnostics12071753openalex-snapshotSimultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter
inferred← citeshttps://doi.org/10.3390/jpm13040682openalex-snapshotOverweight/Obesity Increases the Risk of Overt Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Cirrhotic Patients
inferred← citeshttps://doi.org/10.3390/livers6020026openalex-snapshotAssociation Among Liver Enzymes, Liver-to-Spleen Hounsfield Unit Ratio, and Glycemic Profiles After Sleeve Gastrectomy in Diabetic and Non-Diabetic Japanese Patients with Obesity: A Retrospective Pilot Study
inferred← citeshttps://doi.org/10.3390/nu14061224openalex-snapshotThe Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999–2004
inferred← citeshttps://doi.org/10.3390/nu16010140openalex-snapshotDifferent Associations of Coffee Consumption with the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Liver Fibrosis
inferred← citeshttps://doi.org/10.3748/wjg.v29.i2.286openalex-snapshotScreening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma
inferred← citeshttps://doi.org/10.3803/enm.2022.605openalex-snapshotDPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
inferred← citeshttps://doi.org/10.4093/dmj.2023.0350openalex-snapshotInsulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
inferred← citeshttps://doi.org/10.4103/bjem.bjem_25_24openalex-snapshotFibrosis-4 and Ultrasonography Assessment of Metabolic Dysfunction-associated Steatotic Liver Disease: A Cross-sectional, Observational Study
inferred← citeshttps://doi.org/10.4103/ijem.ijem_1075_25openalex-snapshotEffect of Dapagliflozin on Liver Fat, Liver Stiffness, and Visceral Adiposity in Patients with Type 2 Diabetes Mellitus and MASLD: An Open-Label Study from a Tertiary Care Centre
inferred← citeshttps://doi.org/10.4103/sjg.sjg_199_25openalex-snapshotMetabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards
inferred← citeshttps://doi.org/10.59556/japi.72.0582openalex-snapshotPrevalence and Association of Risk Factors According to Liver Steatosis and Fibrosis Stages among Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus in India: A Cross-sectional Study
inferred← citeshttps://doi.org/10.6084/m9.figshare.26550982openalex-snapshotAdditional file 1 of The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study
inferred← citeshttps://doi.org/10.71079/aside.gi.022626448openalex-snapshotMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multisystemic Narrative Review of Cardiovascular and Oncological Implications
inferred← citeshttps://doi.org/10.7759/cureus.53295openalex-snapshotSignificant Promising Effects of Bariatric Surgery on the Biochemical Control of Glycemia and Lipidemia in Diabetic Patients in Western Saudi Arabia: A Tertiary Center Experience and a Retrospective Study
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID:
icsacinstitute.org/submit.